9. Februar 2022 – Paxlovid is a medicine for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. The EMA concluded that Paxlovid`s benefits are greater than its risks; hence the medicine received a conditional marketing authorisation valid throughout the EU on 28 January 2022. On 2 February 2022 the EMA published a detailed description of the activities and interventions designed to identify, characterise, prevent or minimise risks relating to the medicine Paxlovid.

For more information, see here.